Zekiye Aydoğdu

Zekiye Aydoğdu

Auto-generated profile, based on publicly available information

Zekiye Aydoğdu

Department of Thoracic Surgery, Kars Harakani State Hospital, Kars, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Balkan Medical Journal
Verified
Journal Article
Open access
DYDemet Yaldız
Demet Yaldız
ŞKŞeyda Örs Kaya
Şeyda Örs Kaya
KCKenan Can Ceylan
Kenan Can Ceylan
AAArkın Acar
Arkın Acar
ZAZekiye Aydoğdu
Zekiye Aydoğdu
SYSadık Yaldız
Sadık Yaldız
Predominant histologic subtypes have been reported as predictors of survival of patients with pulmonary adenocarcinoma. To evaluate the predictive value of histologic classification in resected lung adenocarcinoma using the classification systems proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and World Health Organization (2015). Cross-sectional study. The histologic classification of a large cohort of 491 patients with resected lung adenocarcinoma (stages I-III) was retrospectively analyzed. The tumors were classified according to their predominant component (lepidic, acinar, papillary, solid, micropapillary, and mucinous), and their predictive values were assessed for clinicopathologic characteristics and overall survival. The patient cohort comprised 158 (32.2%) patients with solid predominant, 150 (30.5%) with acinar predominant, 80 (16.3%) with papillary predominant, 75 (15.3%) with lepidic predominant, 22 (4.5%) with mucinous, and 5 (1.0%) with micropapillary subtype, and 1 (0.2%) with adenocarcinoma in situ. Overall 5-year survival of 491 patients was found to be 51.8%. Patients with lepidic, acinar, and mucinous adenocarcinoma had 70.9%, 59.0%, and 66.6% 5-year survival, respectively, and there was no statistically significant difference between them. Whereas patients with solid, papillary, and micropapillary predominant adenocarcinoma had 41.0%, 40.5%, and 0.0% 5-year survival, respectively. Compared to other histologic subtypes, patients with solid and papillary predominant adenocarcinoma had significantly lower survival than those with lepidic (p<0.001, p=0.002), acinar (p<0.001, p=0.008), and mucinous (p=0.048, p=0.048) subtypes, respectively. The survival difference between patients with solid subtype and those with papillary subtype was not statistically significant (p=0.67). Solid and papillary histologic subtypes are poor prognostic factors in resected invasive lung adenocarcinoma.

1 February 2021 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
SESinem Ermin
Sinem Ermin
ÖBözgür Batum
özgür Batum
MGMerve Saka Güvenç
Merve Saka Güvenç
Gülden DinizGülden Diniz
Gülden Diniz
AAAYSU AYRANCI
AYSU AYRANCI
UYUfuk Yılmaz
Ufuk Yılmaz

29 November 2019 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
IAIbrahim Onur Alici
Ibrahim Onur Alici
ZAZekiye Aydogdu
Zekiye Aydogdu
Adrenal tumor,EBUS-TBNA,EUS-FNA,non-small cell lung cancer,staging procedures

25 September 2019 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
ACAli Kadri Cirak
Ali Kadri Cirak
KCKenan Can Ceylan
Kenan Can Ceylan
YVYelda Varol
Yelda Varol
GKGülistan Karadeniz
Gülistan Karadeniz
ZAZekiye Aydogdu
Zekiye Aydogdu
EYEnver Yalniz
Enver Yalniz
Turkthoracj, Turkish Thoracic Journal

1 January 2024 in Turkish Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
OUOzan Usluer
Ozan Usluer
ÖGÖzde Elif Gökbayrak
Özde Elif Gökbayrak
AEAylin Erol
Aylin Erol
TATekincan Aktaş
Tekincan Aktaş
GBGüntug Batıhan
Güntug Batıhan
SASafiye Aktaş
Safiye Aktaş
Background: In this study, we aimed to investigate the prognostic value of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and programmed cell death ligand 2 (PD-L2) expressions on immune and cancer cells in terms of survival in patients with lung adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Methods: Between January 2000 and December 2012, a total of 191 patients (172 males, 19 females; mean age: 60.3±8.4 years; range, 38 to 78 years) who were diagnosed with non-small cell lung cancer and underwent anatomic resection and mediastinal lymph node dissection were retrospectively analyzed. The patients were evaluated in three groups including lung squamous cell carcinoma (n=61), adenocarcinoma (n=66), and large-cell carcinoma (n=64). The survival rates of all three groups were compared in terms of immunohistochemical expression levels of PD-1, PD-L1, and PD-L2. Results: The mean follow-up was 71.8±47.9 months. In all histological subtypes, PD-1 expressions on tumor and immune cells were observed in 33% (61/191) and in 53.1% (102/191) of the patients, respectively. Higher expression levels of PD-L1 and PD-L2 at any intensity on tumor and immune cells were defined only in lung adenocarcinomas, and PD-L1 and PD-L2 values were detected in 36.4% (22/64) of these patients. The PD-L1 expressions on tumor and immune cells were observed in 41.7% (10/24) and 25% (6/24) of the patients, respectively. The PD-L2 expressions on tumor and immune cells were detected in 16.7% (4/24) and 8.4% (2/24) of the patients, respectively. Univariate and multivariate analyses revealed that PD-1 expression in tumor cells was an independent prognostic factor in all histological subtypes. Conclusion: Our study results suggest that PD-1 expression is a poor prognostic factor for overall survival in patients with completely resected adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.